Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Completed · Phase 1/Phase 2

Conditions studied: Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma

In brief

The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).

Key facts

Study ID

NCT02302157

Run by

Lineage Cell Therapeutics, Inc.

People needed

25

Starts

2015-03-01

Expected to finish

2018-12-01

Last updated by the study team

2021-07-14

Who can join

Age: 18 and older, up to 69. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Univ. of California at San Diego — La Jolla, California, United States
• Rancho Los Amigos/USC — Los Angeles, California, United States
• Stanford University/Santa Clara Valley Medical Center — San Jose, California, United States
• Shepherd Center — Atlanta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• Washington University — St Louis, Missouri, United States
• Thomas Jefferson University/Magee Rehabilitation — Philadelphia, Pennsylvania, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.